EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

TMBclaw: tumor clone-aware graph learning improves immunotherapy response prediction across heterogeneous cohorts

Yixuan Wang iD, Tianyi Zhu, Xiaofeng Song iD, Peng Chen, Xiaoyan Zhu, Zhili Chang, Xiaonan Wang, Xin Lai, Jiayin Wang iD

Briefings in Bioinformatics · 2025

DOI: 10.1093/bib/bbaf578 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Briefings in Bioinformatics, 2025. Verfasst von Yixuan Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, College of Automation Engineering, Nanjing University of Aeronautics and Astronautics, 29 Jiangjun Avenue, Jian…. Hauptthemen laut MEDLINE: Immunotherapy, Biomarkers, Tumor, Neoplasms, Lung Neoplasms. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have emerged as a cornerstone of modern oncology, necessitating the development of robust biomarkers for optimizing patient stratification and treatment selection. While tumor mutation burden (TMB) has demonstrated prognostic value, conventional quantification methods based on mutation counts fail to reflect immunogenic neoantigen presentation due to intratumoral clonal heterogeneity. Recent efforts have focused on mutation subsets derived from tumor clonality, yet the complex interactions among clones remain a significant obstacle to accurate prognosis. This challenge is further exacerbated by the inherent constraints of limited cohort sizes in clinical studies, which severely compromise model generalizability across heterogeneous cohorts. Therefore, we propose TMBclaw (Tumor Mutation Burden–based Clonal attention with Laplacian Adaptive Weighting), a graph-regularized multi-task learning framework for immunotherapy response prediction. TMBclaw establishes unified integration of group-structured cohorts while enabling cross-cohort knowledge transfer and clonal relationship exploration. For clinical validation, we utilized four cohorts of 238 patients with non–small-cell lung cancer (NSCLC), melanoma, or nasopharyngeal carcinoma treated with ICIs, along with external multicenter validation cohorts (N = 1433) of melanoma and NSCLC patients from public datasets. Comparative analyses demonstrate that TMBclaw significantly outperforms conventional methods in prognostic accuracy and risk stratification. Through systematic quantification of clonal dynamics and discriminative identification of driver clones, TMBclaw shows potential to improve understanding of tumor heterogeneity and provides interpretable insights into the immunotherapy process.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyBiomarkers, TumorNeoplasmsLung NeoplasmsHumansMutationCohort StudiesPrognosisImmune Checkpoint InhibitorsCarcinoma, Non-Small-Cell LungMelanoma

Stichwörter der Autor:innen

clinical decision-makinggraph Laplacian regularizationmulti-task learningtumor clonal heterogeneitytumor mutation burden

Substanzen

Biomarkers, TumorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Biomedical Engineering, College of Automation Engineering, Nanjing University of Aeronautics and Astronautics, 29 Jiangjun Avenue, Jiangning, Nanjing 211106, Jiangsu, China.
  • School of Computer Science and Technology, Faculty of Electronics and Information Engineering, Xi'an Jiaotong University, 28 Xianning West Road, Beilin, Xi'an 710049, Shaanxi, China.
  • College of Computer Science and Technology, Zhejiang University, 866 Yuhangtang Rd, Hangzhou 310058, Zhejiang, China.
  • Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., 128 Huakang Road, Pukou, Nanjing 210032, Jiangsu, China.

ORCID-Profile: Yixuan Wang, Xiaofeng Song, Jiayin Wang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, Y., Zhu, T., Song, X., Chen, P., Zhu, X., Chang, Z., Wang, X., Lai, X., & Wang, J. (2025). TMBclaw: tumor clone-aware graph learning improves immunotherapy response prediction across heterogeneous cohorts. Briefings in Bioinformatics. https://doi.org/10.1093/bib/bbaf578

Vancouver

Wang Y, Zhu T, Song X, Chen P, Zhu X, Chang Z, et al. TMBclaw: tumor clone-aware graph learning improves immunotherapy response prediction across heterogeneous cohorts. Briefings in Bioinformatics. 2025. doi:10.1093/bib/bbaf578

BibTeX
@article{Wang2025,
  author = {Wang, Yixuan and Zhu, Tianyi and Song, Xiaofeng and Chen, Peng and Zhu, Xiaoyan and Chang, Zhili and Wang, Xiaonan and Lai, Xin and Wang, Jiayin},
  title = {TMBclaw: tumor clone-aware graph learning improves immunotherapy response prediction across heterogeneous cohorts},
  journal = {Briefings in Bioinformatics},
  year = {2025},
  doi = {10.1093/bib/bbaf578}
}
Kostenlos starten →